GTOG – Gentamicin in the Treatment of Gonorrhoea

GTOG – Gentamicin in the Treatment of Gonorrhoea opening soon

Introduction: A randomised controlled trial to compare the clinical effectiveness and safety of gentamicin and ceftriaxone in the treatment of gonorrhoea

The G-TOG study will be open to recruitment between September 2014 and October 2016 across multiple sites. Our aim is to recruit 720 patients from 8 UK participating centres to determine whether gentamicin is an acceptable alternative to ceftriaxone, in the treatment of gonorrhoea. Professor Jonathan Ross has said “any patient attending any of  these sexual health clinics who test positive for gonorrhoea and meet the protocol eligibility criteria will be approached to join this very important study”We will add more information quarterly as the study progresses but please do contact us if you have any queries or would like further information.  Further information on the G-TOG  study can be found by emailing Jan Harding: Jan.Harding@uhb.nhs.uk

Thank you for your interest,
The G-TOG study team

News articles:

• ‘Slowdown’ in resistant gonorrhoea (BBC News)
• Action on ‘untreatable’ gonorrhoea (BBC News)
• Gonorrhoea named urgent public health threat in U.S. as it becomes drug-resistant (Daily Mail)

Supporting information:

• Antimicrobial Resistance Data – Gonorrhoea
• Emergence of multi-drug resistant Neisseria gonorrhoeae – Threat of global rise in untreatable sexually transmitted infections (Fact sheet)
• CDC Labels Antibiotic-Resistant Gonorrhea an ‘Urgent Threat’
• Antibiotic-Resistant Gonorrhea
• Efforts to tackle gonorrhoea treatment resistance may be working, but threatened by ongoing transmission